Match Document Document Title
US20150361134 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION  
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
US20140342977 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION  
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
US20120064034 Peptidomimetic protease inhibitors  
The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors;...
US20110117057 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS  
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
US20100016241 METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION  
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met...
US20140294796 AROMATIC-CATIONIC PEPTIDES AND USES OF SAME  
The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to...
US20140206839 CROSS LINKED HYALURONIC ACID-SILK AND USES THEREOF  
The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such...
US20140056847 INHIBITORS OF SERINE PROTEASES  
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers...
US20130316945 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE  
The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus...
US20130224228 Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods  
Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis;...
US20130177531 Inhibitors of Serine Proteases  
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers...
US20120244174 TREATMENT OF TAUOPATHIES  
The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the...
US20120171210 METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION  
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met...
US20120065149 Vitamin receptor binding drug delivery conjugates  
The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker...
US20110262366 COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE  
The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use....
US20110171175 INHIBITORS OF SERINE PROTEASES  
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers...
US20110086006 HCV NS3-NS4 Protease Resistance Mutants  
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
US20110076234 PEPTIDES COMPRISING AN ISODGR MOTIF  
Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit αvβ3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
US20090247608 Targeting Lipids  
The present invention provides targeting lipids of structure L100—linker—L101 (CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or...
US20090131326 ABUSE-RESISTANT AMPHETAMINE PRODRUGS  
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for...
US20090074828 POLY(AMINO ACID) TARGETING MOIETIES  
The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of...
US20080138278 CONJUGATES OF RGD PEPTIDES AND PORPHYRIN OR (BACTERIO) CHLOROHYLL PHOTOSYNTHESIZERS AND THEIR USES  
Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT),...
US20080004429 Insulinotropic peptide synthesis using solid and solution phase combination techniques  
The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing...
US20070105781 Inhibitors of serine proteases  
This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers...
US20070060527 Orally administered small peptides synergize statin activity  
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are...
US20050164950 Orally administered small peptides synergize statin activity  
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are...
US20130165631 BISAMINOETHANETHIOL-TARGETING LIGAND CONJUGATES AND COMPOSITIONS  
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use...
US20130122024 NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF  
The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes...
US20120004720 G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES  
This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain...
US20110166063 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES  
The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of...
US20090186825 ABUSE-RESISTANT AMPHETAMINE PRODRUGS  
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for...
US20090137489 ABUSE-RESISTANT AMPHETAMINE PRODRUGS  
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for...
US20090137488 ABUSE-RESISTANT AMPHETAMINE PRODRUGS  
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for...
US20090131324 ABUSE-RESISTANT AMPHETAMINE PRODRUGS  
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for...
US20080199481 COMPOUNDS  
The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including...
US20070033669 Semaphorin gene family  
A novel class of proteins, semaphorins, nucleic acids encoding semaphorins, semaphorin peptides, and methods of using semaphorins and semaphorin-encoding nucleic acids are disclosed. Semaphorin...
US20140058064 MULTI-DRUG LIGAND CONJUGATES  
Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of...
US20140058063 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES  
The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker...
US20130184435 MULTI-DRUG LIGAND CONJUGATES  
Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of...
US20110262347 METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS  
Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
US20080312158 Semaphorin Gene Family  
A novel class of proteins, semaphorins, nucleic acids encoding semaphorins, semaphorin peptides, and methods of using semaphorins and semaphorin-encoding nucleic acids are disclosed. Semaphorin...
US20060240562 CLEAVABLE SURFACTANTS AND METHODS OF USE THEREOF  
Cleavable compositions and methods of use especially in MALDI MS analysis of hydrophobic proteins.
US20150315237 NMDA Receptor Modulators and Uses Thereof  
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning,...
US20140066594 BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS  
Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin...
US20130096074 PROTEIN HYDROLYSATE ENRICHED IN PEPTIDES INHIBITING DPP-IV AND THEIR USE  
Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an...
US20130005943 Methods for Preparing Internally Constrained Peptides and Peptidomimetics  
The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region and a method of...
US20110040072 MONO AND DI-SUBSTITUTED OXYCODONE COMPOUNDS AND COMPOSITIONS  
The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to oxycodone in a manner that substantially decreases the potential for overdose. When...
US20100210567 USE OF A TUFTSIN AS A THERAPEUTIC AGENT  
The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic...
US20090110662 MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER  
The present invention relates to the field of polymer chemistry and more particularly to click-functionalized targeting compounds and methods for using the same.
US20090047654 Polymer affinity matrix, a method for the production and use thereof  
A polymer affinity matrix for the binding of one or more substances in a fluid or removing said substance(s) from the fluid and/or decreasing the amount or concentration thereof in said fluid with...